sprite-preloader
Anzeige
Mehr »
Sonntag, 19.11.2017 Börsentäglich über 12.000 News von 570 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von Endpoints News

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrScPharmaceuticals raises $90M in IPO with heart failure drug on deck
FrUK research campus expands; FDA clears NGS test for tumors; Orphazyme raises €80 million IPO
FrPfizer reshuffles top ranks with Albert Bourla as COO; Intra-cellular nabs Novartis vet Andrew Satlin as CMO
FrAnnalisa Jenkins' next career chapter takes her back to Europe
FrA go-go FDA is opening up the fast lane to regenerative med approvals
FrBooming Regeneron gets the green light for a major expansion
FrWhat's a successful failure? Atlas' Booth sounds taps for Merck-backed Quartet Medicine
DoFDA clears next-gen tumor sequencing test from Memorial Sloan Kettering
DoThe Pentagon's compromise: drug approvals to remain in FDA's hands
DoIn roundhouse blow to Shire, Roche bags an FDA OK for its blockbuster hemophilia A prospect
DoMerck partners up on T-cell tech platform in $374M autoimmune deal; Turnstone taps BMS vet Mike Burgess for top R&D role
DoLet the jousting begin: Which top cancer R&D companies are looking to make a splash at ASH?
DoArsanis prices $40M IPO for infectious disease work
DoFDA, EMA put a star CAR-T from bluebird and Celgene on the VIP list
DoX4 raises $27M to take Sanofi's old drug through pivotal trial
DoJohns Hopkins has $65M to spend on taking their drugs right up to human studies
DoJ&J goes back to Ionis for its second experimental pill for a GI autoimmune disease
DoYou want to charge $1M for that gene therapy? Here's where you're wrong
DoNot your mom's probiotic: Google-backed Evelo teams up with Mayo Clinic on bug drugs
MiUltragenyx lands first FDA OK, with another on the horizon in shift to commercial ops
MiModerna kicks off mRNA cancer vaccine study; Biotech stocks were checked this month - but that's a good thing
MiAlkermes touts equal efficacy of monthly Vivitrol against daily Suboxone
MiGenentech inks $650M deal with protein degradation pioneer Arvinas
MiFatal sepsis attacks mar Acorda's PhIII, triggering new safety measures and a pause on enrollment
Mi$49M round; experienced team; A-list VCs - Inozyme launches with rare disease strategy and a yen for bigger things to come